




1Q 2022 Executive Summary and General Comments

29 April 2022



1. Net Profit refers to Profit attributable to Owners of the Company
2. Earnings per share (EPS) is on a fully diluted basis
3. As at 31 March 2022

Broad-Based YoY Growth Across Domains




Portfolio A



1. Life Science, Genomics, Molecular Diagnostics and Related Materials Technology	Growth
2. Medical Devices and Equipment	Growth
3. Healthcare & Wellness Technology, Lifestyle Consumer Tech, Health Improvement Products and Others	Growth
Overall Portfolio A Performance	Growth

Portfolio B

4. Instrumentation, Test & Measurement Technology	Growth
5. Networking & Communications, Security & Safety, Building Automation, Industrial IOT	Flat
6. Advanced Payment Systems	Growth
7. Computing & Productivity Systems, Advanced Industrial Technology, Printing & Imaging, Related Components Technology and Others	Growth
Overall Portfolio B Performance	Growth

 Diversified across more than 100 customers

Financial Performance





FINANCIAL PERFORMANCE REVIEW

1Q 2022 Results – YoY Comparison



(S\$m)	1Q 2022	1Q 2021	%
Revenue	889.3	686.7	29.5
Profit before tax	102.6	75.0	36.9
PBT Margin (%)	11.5	10.9	-
Income tax expense	(18.5)	(9.6)	91.5
Effective Tax Rate (%)	18.0	12.9	-
Net Profit	84.0	65.3	28.6
Net Margin (%)	9.5	9.5	-
Earnings Per Share (cents)	28.8	22.4	28.8



FINANCIAL POSITION AND CASH FLOW


Balance Sheet Highlights



(S\$m)	31 March 2022	31 December 2021
Cash & Bank Balances	815.1	807.9
Net Current Assets	1,920.9	1,830.0
Net Non Current Assets	885.0	889.4
Total Net Assets	2,805.8	2,719.5
Accumulated Profits	2,031.3	1,948.3
Share Capital & Reserves	771.3	768.0
Non-Controlling Interests	3.2	3.1
Total Equity	2,805.8	2,719.5
Net Asset Value per share	S\$9.64	S\$9.35

Changes in Working Capital

(S\$m)	31 March 2022	31 December 2021
Trade Receivables	860.3	829.2
Trade Payables	(673.0)	(643.6)
AR- AP	187.3	185.7
Inventories	1,152.6	1,049.4
Working Capital	1,340.0	1,235.1

 The Group continues to hold higher inventories to support customers' orders in the coming quarters



OUTLOOK



Venture has commenced the year positively. Based on its customers' orders and forecasts, Venture anticipates a steady demand outlook across its various technology domains such as Lifestyle & Wellness, Life Science, Instrumentation, Test & Measurement Technology and Advanced Industrial domains. Recent new product launches have been well received by end-customers and have contributed to additional growth. Several initiatives by our R&D Labs have enabled us to mitigate supply chain disruptions and expand our capabilities to fulfil more orders.

The uncertainties in the operating environment are expected to remain in the near term. The Group will continue to proactively monitor the situation and be ready to resolve challenges as and when they arise.

Venture remains optimistic about its long-term prospects. Over the years, the Group has gained good traction in selected ecosystems of interests, becoming a leading technology partner of choice for many global players. Going forward, Venture will continue to invest in new capabilities, strengths and talents to accelerate growth of its Clusters of Excellence globally.

This presentation may contain certain forward-looking statements including, but not limited to, statements as to future operating results and plans.

These statements are based on our assumptions and estimates and are subject to known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Group to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements.

Consequently, readers are cautioned not to place undue reliance on any forward-looking statements.



Thank You

For enquiries, please contact:

Judy Tan

Investor Relations & Corporate Communications

+65 6484 8136

judy.tan-th@venture.com.sg